METANEURON: Closes RMB 10M-Plus Series A for Electrode PSG
NewTimeSpace News: On 16 November 2026, Beijing MetaNeuron Technology Co., Ltd. (METANEURON, unlisted) closed a Series A round of above RMB 10 million, invested by Taiyi Investment. The company had earlier received angel funding from Lingyi Capital and pre-A funding from Aeonmed; the exact amount and post-money valuation of this round were not disclosed. Proceeds will mainly fund hospital access and out-of-hospital promotion of its dry-electrode polysomnography (PSG) system, development of sleep-and-disease association diagnostic models, and research on neuromodulation products.
MetaNeuron was founded in May 2022 and is headquartered in Beijing's Chaoyang district, positioning itself as a sleep brain-computer interface company built on full-channel EEG. Founder Dong Yanbin was previously a partner at non-invasive brain-computer interface company Naolu Technology, where he led the approval of China's first medical registration certificate for a brain-computer headband, and before that a core R&D member at Airdoc, working on the country's first class-III certificate for AI-assisted fundus diagnosis.
Its lead product is a full-channel dry-electrode PSG device that combines a serious medical use with a consumer form factor. It follows American Academy of Sleep Medicine standards, requires no conductive paste, and can be fitted by a briefly trained nurse or by the patient in as little as ten minutes, with data collected at primary-care sites and read remotely by senior physicians under a medical alliance model. The company says correlation between its dry and wet electrode raw signals reaches 0.97, and that the product, which has obtained a medical device registration certificate and a production licence, is the world's first dry-electrode full-channel PSG to be registered; it is already selling into hospitals, with dozens of hospitals having validated it clinically. Outside hospitals, the company has started pilots with a leading internet healthcare platform, under which platform doctors write orders and nurses guide patients at home.
Neuromodulation is its other core pipeline and has entered investigator-initiated clinical work: anxiety and panic disorder is led by the Second Xiangya Hospital, obstructive sleep apnoea is being studied with Peking University First Hospital after small-sample human pilot work, depression-related memory modulation is progressing with Peking University Sixth Hospital, and N3 deep-sleep enhancement and early Alzheimer's sleep modulation remain at prototype stage. After the round, the company says it will focus on three tasks: clinical and pre-registration work for the neuromodulation pipeline, construction of a production base in Hunan, and continued development of AI diagnostic software and a sleep foundation model plus CE and FDA preparation for a second-generation product. Liu Ziyu, investment director at Taiyi Investment, said sleep is among the settings best suited to accumulating long-term continuous data, and that the team spent four years building the hardware base before scaling a deliverable medical product.